Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
HB0036
/
Zhejiang Huahai Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
HB0036
/
Zhejiang Huahai Pharma
A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.
() - Apr 24, 2024 - Abstract #ASCO2024ASCO_5526;
P1/2
Based on these data, phase II monotherapy and combination studies are in preparation. Clinical trial information: NCT05417321.
|||
|||||||
HB0036
/
Zhejiang Huahai Pharma
Enrollment open, Metastases:
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov) - Aug 30, 2022
P1/2
, N=80, Recruiting,
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trial information: NCT05417321. Not yet recruiting --> Recruiting
||||
||||||
HB0036
/
Zhejiang Huahai Pharma
New P1/2 trial, Metastases:
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov) - Jun 14, 2022
P1/2
, N=80, Not yet recruiting,
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.